Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Slides:

Advertisements

Similar presentations

Triple-Negative Breast Cancer

Advertisements

Results grade1 grade2 grade3 (1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters? Alex-CIS-GCTOF.

FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.

Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.

Epigenetic Control of Tamoxifen Resistant Breast Cancer Kristin Williams Arcaro Lab Thesis Resarch June 25, 2012 Kristin Williams Arcaro Lab Thesis Resarch.

GeneGroupAnalysis BetaCS Alejandro Quiroz-Zárate John Quackenbush lab

Breast Cancer: BRCA1/2 Erin Hayes Foundations of Medicine Blue Valley CAPS October 28,

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

IN CANCER MOLECULAR DETECTION. WHAT DO THEY DETECT? Specific proteins Expression of certain genes Mutations Epigenetic Changes.

Triple negative (TN) vs. positive (TP) breast cancer (BC) analysis with public genomic data yields AGR3 as a biomarker Anita Umesh, Jenny Park, James Shima,

Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,

Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. (A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time.

Supplementary Table 1. A)Patient details for Fresh Frozen test cohort, B) Patient details for validation cohort Age Median64 Range41-89 Grade

THE GENETIC BASIS OF CANCER

Number of brain metastasis

Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.

Figure 1 The heterogenous landscape of triple-negative breast cancer

TRIPLE NEGATIVE BREAST CANCER (TNBC) & ETHNIC MINORITIES

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Prognostic significance of tumor subtypes in male breast cancer:

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

Fig. 8. Response to aromatase inhibitor and cyclin dependent kinase inhibitor in metastatic hormone receptor+, HER2 negative breast cancer. In this 29-year-old.

Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21.

Figure 1. Microscopic findings and karyotyping

Transcriptional heterogeneity of breast cancer subtypes,

Genetics In Breast Cancer

Invasive Breast Cancer Preferably and Predominantly Occurs at the Interface Between Fibroglandular and Adipose Tissue Wenlian Zhu, Susan Harvey, Katarzyna.

Hallett, et al., - Supplementary Figure 1

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors Anita Muthukaruppan, Annette Lasham,

Table (1):Relation between lymph node and molecular subtypes.

Figure 1. MORT gene silencing is early event in cancer

Figure S1. DCYTB expression is higher in ER+ than ER- patients

A Functional Map of Oncogenic States for Breast Cancer

Figure 1 Comparison of tumor size at time of excision between axillary node-negative, axillary node-positive, and distant metastasis subgroups of basal-like.

سرطان الثدي Breast Cancer

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Uncovering a Tumor Suppressor for Triple-Negative Breast Cancers

Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Volume 17, Issue 1, Pages (September 2016)

Handling and Evaluation of Breast Cancer Biopsy

Volume 3, Issue 4, Pages (April 2003)

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

Working with RNA-Seq Data

JNK signature in breast cancer cells is linked to ECM, stem cell, and wound healing gene networks and is enriched in basal‐like breast cancer JNK signature.

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

Erratum Journal of Thoracic Oncology

Volume 10, Issue 6, Pages (December 2006)

Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked

Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.

20-Year Risks of Breast-Cancer Recurrence

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.

Correlation between Pten/p53 status and AKT pathway activity in BC and effect on clinical outcome Box plot for p53‐pathway activity in p53 wild‐type and.

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

Optoacoustic Imaging and Gray-Scale US Features of Breast Cancers: Correlation with Molecular Subtypes Total external optoacoustic US feature scores of.

Nadia Howlader, PhD National Cancer Institute

Figure 1. Chloride channel-3 (CIC-3) expression in breast tumor tissues. (A) Chloride channels (ClC-1–7, CFTR) are expressed in human breast cancer tissues.

Figure 4. Effects of chloride channel-3 (ClC-3) knockdown on the expression of cell cycle-regulatory proteins. (A) Representative western blot images of.

Clustering analysis of DTC-associated genes.

Volume 28, Issue 3, Pages e7 (July 2019)

MYC and LYN are coexpressed and have interdependent clinical outcomes.

Subtype classification of breast functional screening results.

CD36 expression is coordinately regulated in multiple cellular compartments. CD36 expression is coordinately regulated in multiple cellular compartments.

Volume 3, Issue 4, Pages (April 2003)

Presentation transcript:

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus MORT copy number. DNA methylation of the MORT promoter in receptor negative and receptor positive tumors estrogen receptor (ER) (B), progesterone receptor (PR) (C), and human epidermal growth factor receptor 2 (HER2) (D). (E) DNA methylation of the MORT promoter in triple negative (TN) tumors, tumors positive for at least one receptor and a group of normal samples (p-value is for contrast TN vs. receptor (+) tumors). (F) DNA methylation of the MORT promoter in breast tumors classified into subtypes according to PAM50 (p-values are for contrast of individual tumor subtypes vs. normal). (G) DNA methylation of the MORT promoter in samples from patients >60 years of age compared to those from patients ≤60. (H) Association between amplification of the cyclin D1 locus and DNA methylation of the MORT promoter. (I) DNA methylation of the MORT promoter in samples with wild type TP53 compared to samples with mutated TP53. (J) DNA methylation of the MORT promoter in samples with wild type GATA3 compared to samples with mutated GATA3. RPKM=reads per kilobase per million; CN=copy number; WT=wild type. Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus MORT copy number. DNA methylation of the MORT promoter in receptor negative and receptor positive tumors estrogen receptor (ER) (B), progesterone receptor (PR) (C), and human epidermal growth… J Breast Cancer. 2017 Jun;20(2):198-202. https://doi.org/10.4048/jbc.2017.20.2.198